

Supervisory Board Report

The fiscal year 2018 was marked by the implementation of the strategic agenda and the IPO of capsensixx AG. In the course of the 2018 financial year, the Supervisory Board carefully monitored the management of capsensixx AG and performed the duties incumbent on it by law and the Articles of Association. We are in continuous dialogue with the company's management board. We were briefed by the Management Board in the Supervisory Board meetings as well as by additional written and verbal reports on all relevant issues of corporate planning and strategic development, the earnings, assets and financial position as well as the current business policy, the risk management system and the risk situation. This happened regularly, promptly and comprehensively. The Supervisory Board was involved immediately and in good time in all decisions that were of fundamental importance to the company. In the period under review, a total of eight meetings of the Supervisory Board were held at regular intervals, in which all members of the Supervisory Board participated. In doing so, the Supervisory Board discussed the business situation of the company, the strategic orientation as well as the development opportunities and business risks in detail with the Management Board. The Supervisory Board approved the measures that require the approval of the Supervisory Board in accordance with the Articles of Association and / or the law. As the Supervisory Board consists of only three persons, no committees were formed. In the course of the financial year 2018, the Supervisory Board dealt, among other things, with the following matters:

Decisions during the year

The organizational structure of the company was the content of several meetings. The Management Board and the Supervisory Board have discussed how revenue can be increased and efficiency can be increased. On 21st of June 2018, the IPO of capsensixx AG was processed accompanied with its listing. The Supervisory Board unanimously approved the reports of the Management Board on the business transactions incurred.

Annual Financial Statements and Management Report

The annual financial statements and management report of capsensixx AG prepared in accordance with German accounting standards and the consolidated financial statements and group management report for the period from January 1, 2018 to December 31, 2018 prepared in accordance with International Financial Reporting Standards (IFRS) and have been audited by Baker Tilly GmbH & Co. KG Wirtschaftsprüfungsgesellschaft, Frankfurt / Main, providing an unqualified audit opinion. The corresponding auditor's reports were submitted to the Supervisory Board at its balance sheet meeting.

The auditor attended the meeting of the Supervisory Board and reported on the key findings of his audit, including his independence. The Supervisory Board acknowledged and approved the report of the auditor.

The Supervisory Board

- has not raised any objections after concluding its own audit and has endorsed the findings of the auditors.
- approved the annual financial statements and the consolidated financial statements
- at its meeting on April 17, 2019, and thus approved the annual financial statements.
- agrees with the proposal of the Management Board to carry forward the net loss for the year of capsensixx AG of € 1,085,058.11 to new account.

The Supervisory Board would like to thank the Management Board, the officers and the employees for their dedication. The Supervisory Board thanks the customers and shareholders of capsensixx AG for the trust they have placed in the Supervisory Board.

Frankfurt, April 17th, 2019

Martin Stürner